Literature DB >> 8617139

Hepatic encephalopathy after transjugular intrahepatic portosystemic shunt. Incidence and risk factors.

O Riggio1, M Merlli, G Pedretti, R Servi, P Meddi, R Lionetti, P Rossi, M Bezzi, F Salvatori, U Ugolotti, F Fiaccadori, L Capocaccia.   

Abstract

Forty-seven consecutive patients were prospectively evaluated to study the incidence of hepatic encephalopathy as well as modifications in the PSE index after TIPS. Various clinical, laboratory, and angiographic parameters were also recorded to identify risk factors for the development of post-TIPS hepatic encephalopathy (HE). Mean follow-up was 17 +/- 7 months. During follow-up, six patients died and one underwent transplantation. All other patients were followed for at least a year. Fifteen patients (32%) experienced 20 acute episodes of precipitated HE (hospitalization was necessary in 10 instances), and five patients (11%) presented a continuous alteration in mental status with frequent spontaneous exacerbation during follow-up. Both precipitated and spontaneous HE occurred more frequently during the first three months of follow-up. Moreover the PSE index was significantly worse than basal values one month after TIPS, thereafter returning to near basal values. HE was successfully treated in all patients but one who required a reduction in the stent/shunt diameter. Increasing age (>65 years) and low portacaval gradient (<10 mm Hg) were predictors of HE after TIPS. A gradual dilation of the stent/shunt should be performed to obtain a portacaval gradient >10 mm Hg to avoid an unacceptable rate of HE after TIPS.

Entities:  

Mesh:

Year:  1996        PMID: 8617139     DOI: 10.1007/bf02282344

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  16 in total

1.  Hepatic encephalopathy and treatment of oesophageal varices.

Authors:  L S Eriksson
Journal:  Scand J Gastroenterol       Date:  1988-08       Impact factor: 2.423

2.  Portal-systemic encephalopathy and portacaval anastomosis: a prospective, controlled investigation.

Authors:  M G Mutchnick; E Lerner; H O Conn
Journal:  Gastroenterology       Date:  1974-05       Impact factor: 22.682

3.  Creation of transjugular intrahepatic portosystemic shunts with the wallstent endoprosthesis: results in 100 patients.

Authors:  J M LaBerge; E J Ring; R L Gordon; J R Lake; M M Doherty; K A Somberg; J P Roberts; N L Ascher
Journal:  Radiology       Date:  1993-05       Impact factor: 11.105

Review 4.  Portal-systemic encephalopathy (PSE) after transjugular intrahepatic portal-systemic stent-shunts (TIPS).

Authors:  H Conn
Journal:  Ital J Gastroenterol       Date:  1993 Aug-Sep

5.  Emergency transjugular intrahepatic portasystemic stent shunting as salvage treatment for uncontrolled variceal bleeding.

Authors:  P A McCormick; R Dick; E B Panagou; J K Chin; L Greenslade; N McIntyre; A K Burroughs
Journal:  Br J Surg       Date:  1994-09       Impact factor: 6.939

6.  Hemodynamic events in a prospective randomized trial of propranolol versus placebo in the prevention of a first variceal hemorrhage.

Authors:  R J Groszmann; J Bosch; N D Grace; H O Conn; G Garcia-Tsao; M Navasa; J Alberts; J Rodes; R Fischer; M Bermann
Journal:  Gastroenterology       Date:  1990-11       Impact factor: 22.682

7.  The transjugular intrahepatic portosystemic stent-shunt procedure for refractory ascites.

Authors:  A Ochs; M Rössle; K Haag; K H Hauenstein; P Deibert; V Siegerstetter; M Huonker; M Langer; H E Blum
Journal:  N Engl J Med       Date:  1995-05-04       Impact factor: 91.245

8.  Incidence of shunt occlusion or stenosis following transjugular intrahepatic portosystemic shunt placement.

Authors:  C D Lind; T W Malisch; W K Chong; W O Richards; C W Pinson; S G Meranze; M Mazer
Journal:  Gastroenterology       Date:  1994-05       Impact factor: 22.682

9.  Portosystemic encephalopathy after transjugular intrahepatic portosystemic shunt: results of a prospective controlled study.

Authors:  A J Sanyal; A M Freedman; M L Shiffman; P P Purdum; V A Luketic; A K Cheatham
Journal:  Hepatology       Date:  1994-07       Impact factor: 17.425

10.  [Transjugular intrahepatic porto-systemic shunt (TIPS): indications and results].

Authors:  P Rossi; P Ricci; G Natali; G Pizzi; F Orsi; C Panzetti; M Rossi; O Riggio; M Merli
Journal:  Radiol Med       Date:  1994-05       Impact factor: 3.469

View more
  22 in total

Review 1.  The brain following transjugular intrahepatic portosystemic shunt: the perspective from neuroimaging.

Authors:  Hui Juan Chen; Gang Zheng; Julian L Wichmann; U Joseph Schoepf; Guang Ming Lu; Long Jiang Zhang
Journal:  Metab Brain Dis       Date:  2015-09-24       Impact factor: 3.584

2.  Hepatic encephalopathy following transjugular intrahepatic portosystemic shunt (TIPS): management with L-ornithine-L-aspartate and stent reduction.

Authors:  Vanessa Stadlbauer; Josef Tauss; Horst R Portugaller; Philipp Stiegler; Florian Iberer; Rudolf E Stauber
Journal:  Metab Brain Dis       Date:  2006-12-14       Impact factor: 3.584

3.  Transjugular intrahepatic portosystemic shunt in the management of refractory ascites.

Authors:  Guadalupe Garcia-Tsao
Journal:  Semin Intervent Radiol       Date:  2005-12       Impact factor: 1.513

4.  Unusual sources of gastrointestinal bleeding.

Authors:  Daniel Castresana; Archana Kaza
Journal:  Dig Dis Sci       Date:  2014-12-10       Impact factor: 3.199

5.  No effect of albumin infusion on the prevention of hepatic encephalopathy after transjugular intrahepatic portosystemic shunt.

Authors:  Oliviero Riggio; Silvia Nardelli; Chiara Pasquale; Ilaria Pentassuglio; Stefania Gioia; Eugenia Onori; Camilla Frieri; Filippo Maria Salvatori; Manuela Merli
Journal:  Metab Brain Dis       Date:  2015-08-20       Impact factor: 3.584

6.  Hepatic encephalopathy therapy: An overview.

Authors:  Oliviero Riggio; Lorenzo Ridola; Chiara Pasquale
Journal:  World J Gastrointest Pharmacol Ther       Date:  2010-04-06

Review 7.  Could there be light at the end of the tunnel? Mesocaval shunting for refractory esophageal varices in patients with contraindications to transjugular intrahepatic portosystemic shunt.

Authors:  Jessica Davis; Albert K Chun; Marie L Borum
Journal:  World J Hepatol       Date:  2016-07-08

8.  H-graft portacaval shunts versus TIPS: ten-year follow-up of a randomized trial with comparison to predicted survivals.

Authors:  Alexander S Rosemurgy; Mark Bloomston; Whalen C Clark; Donald P Thometz; Emmanuel E Zervos
Journal:  Ann Surg       Date:  2005-02       Impact factor: 12.969

9.  Transjugular intrahepatic portosystemic shunt for the treatment of medically refractory ascites.

Authors:  Ahmad Parvinian; James T Bui; M Grace Knuttinen; Jeet Minocha; Ron C Gaba
Journal:  Diagn Interv Radiol       Date:  2014 Jan-Feb       Impact factor: 2.630

Review 10.  Pathophysiology and management of pediatric ascites.

Authors:  Mahmoud Sabri; Miguel Saps; John M Peters
Journal:  Curr Gastroenterol Rep       Date:  2003-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.